Allowing immunization of the population - especially infants and in the elderly - against human Metapneumovirus through a recombinant formulation.
Today there is no safe or effective vaccine against human Metapneumovirus in the world, a virus that is present worldwide and causes severe respiratory diseases in children, the elderly and people with immunodeficiency. It is transmitted from one person to another by inhaling small drops from respiratory secretions and is the second leading cause of diseases worldwide associated with respiratory tract infections in children. It is estimated at causing at least 10% of respiratory tract infections that are not related to known etiologic agents.
The proposed solution consists of a recombinant vaccine that will simultaneously induce immune protection against tuberculosis and hMPV. Identification of the virus elements that have to be neutralized by means of a vaccine to prevent respiratory disease has been carried out. We are currently under GMP manufacture of the vaccine for evaluation in clinical trials on humans.
Doctor of Microbiology and Immunology at the Albert Einstein College of Medicine in New York, USA. He then completed two postdoctoral degrees, one at the Albert Einstein College of Medicine and another at The Rockefeller University, New York-USA. He is currently a Full Professor in the Department of Molecular Genetics and Microbiology at the Faculty of Biological Sciences and in the Department of Endocrinology at the Faculty of Medicine of the Catholic University of Chile. He is also scientific adviser to the Senate and representative of the International Center for Molecular Genetics and Biotechnology in Chile.READ MORE
This technology will make it possible to immunize the population - especially the child population - against Human Metapneumovirus, which has a high impact in Chile and worldwide as one of the main causes of respiratory diseases.
Licensing or sale of technology (vaccine package) against human Metapneumovirus (hMPV)